The aim of this project is to develop an oral drug/drug candidate for the treatment of patients with hepatocellular carcinoma (HCC). Hepatocellular Carcinoma, HCC). The action of the proposed small-molecule drug is to consist in the induced degradation of the molecular target - the SALL4 protein, which as a factor regulating the functions of cancer stem cells (CST). Cancer Stem Cells (CSC) plays a significant role in the process of carcinogenesis and progression of HCC. In addition, our research has shown that compounds with the greatest therapeutic potential, apart from the ability to degrade SALL4, selective towards key neosubstrates of the CRC E3 ligase, such as the CRC E3 ligase. Ikaros also have a degrading activity against GSPT1 proteins, involved in the regulation of the protein translation process, and NEK7 protein, controlling the production of pro-inflammatory IL-1beta interleukin with a pro-cancer role. The codegradation of the SALL4, GSPT1 and NEK7 proteins provides significant added value and, due to promising development results, SALL4 degraders with a polypharmacological nature of action have been authorised. In the first phase of the project, the initial stages were carried out in parallel and cyclically. This work included the completion of a targeted library of compounds, which was the subject of iterative studies planned in subsequent stages. The process of designing and selecting structures with optimal properties (determination of the structure-activity relationship, SAR) was supported by ADME/PK research, as well as by research allowing to determine the physicochemical properties of compounds. Work has also been carried out to monitor the activity and selectivity of the compounds developed using biophysical, cellular and animal models in vivo. The above works resulted in the selection of a clinical candidate - CPT-ABS-752 compound, and the selection of a backup compound for toxicological tests in the GLP standard. After the selection of the clinical candidate, the manufacturing process was developed and the synthesis of the selected degrader in the non-GMP standard, and then GMP, was carried out on a larger scale. GLP tox studies were also conducted to comprehensively assess the safety profile of the molecule and determine the no-observed-adverse-effect-level (NOAEL) dose to determine the appropriate dose for Phase 1a clinical trials in patients. In phase II of the project, it is planned to closely continue the work carried out in phase one, through the implementation of tasks aimed at introducing the leading compound CPT-ABS-752 to clinical trials. The specific objectives of Phase 2 are primarily to obtain authorisation for clinical trials, which will require the completion and submission of relevant documentation to the regulatory authority. Phase II also includes the production of capsules containing the active substance. The first series will make it possible to finalise the documentation necessary to obtain the authorisation for the clinical trial, and further production is planned during the clinical trial, which will allow flexibility in the selection of the content of the active substance and the amount of capsules, necessary to carry out dose escalation. Finally, phase two involves the implementation of a multicenter, international, non-randomized phase 1a clinical trial. This will allow the safety of tolerability of CPT-ABS-752 therapy in patients with HCC to be evaluated, as well as the determination of the maximum tolerable dose (MTD) and/or recommended dose up to phase 2 of clinical trials. It should be stressed that Phase II of the project is part of the specific objective under Priority 1. FENG, which is the development and strengthening of research and innovation capacities and the use of advanced technologies. In addition, the planned scope of work in phase II of the project is part of the scope of support provided for in the SMART path action in FENG.